<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Carlsmed, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock</link>
<description>Latest news and press releases for Carlsmed, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/carlsmed-inc-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>Carlsmed, Inc. To Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-upcoming-investor-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-upcoming-investor-conferences</guid>
<pubDate>Tue, 28 Apr 2026 20:01:00 GMT</pubDate>
<description>CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and Chief Executive Officer, will participate in the following investor conferences. Bank of America Global Healthcare Conference in Las Vegas, NV. Fireside chat on Tuesday, May 12, 2026, at 4:20 PM PT. A live webcast will be available to registered participants, and management will host one-on-one meetings on the same day.Jefferies Glob</description>
</item>
<item>
<title>Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-report-first-quarter-2026-financial-results-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-report-first-quarter-2026-financial-results-on-may-5-2026</guid>
<pubDate>Tue, 14 Apr 2026 12:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before the sta</description>
</item>
<item>
<title>Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-the-25th-annual-needham-virtual-conference-7</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-the-25th-annual-needham-virtual-conference-7</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO</description>
</item>
<item>
<title>Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmedr-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmedr-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 25 Feb 2026 21:01:00 GMT</pubDate>
<description>Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the fourth quarter and full year ended December 31, 2025. "We delivered another very strong quarter with 61% revenue growth year-over-year, gross margin e</description>
</item>
<item>
<title>Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results </title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmedr-reports-fourth-quarter-and-full-year-2025-financial-results-1</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmedr-reports-fourth-quarter-and-full-year-2025-financial-results-1</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Fourth quarter revenue of $15.2 million; 61% growth YoY Full year revenue of $50.5 million; 86% growth YoY CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-the-2026-canaccord-genuity-musculoskeletal-conference</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-the-2026-canaccord-genuity-musculoskeletal-conference</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and</description>
</item>
<item>
<title>Carlsmed Announces first corra™ personalized Cervical Plating Procedure</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-announces-first-corratm-personalized-cervical-plating-procedure</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-announces-first-corratm-personalized-cervical-plating-procedure</guid>
<pubDate>Wed, 18 Feb 2026 21:05:00 GMT</pubDate>
<description>The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolioCARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the first personalized cervical plating procedure using the corra™ Cervical Plating System, the latest addition to its portfolio of personalized spine surgery solutions. The procedure, which was performed by Dr. Aaron Clark at the University of California San Francisco (</description>
</item>
<item>
<title>Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-report-fourth-quarter-210100192</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-report-fourth-quarter-210100192</guid>
<pubDate>Wed, 11 Feb 2026 21:01:00 GMT</pubDate>
<description>CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10</description>
</item>
<item>
<title>Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-announces-first-aprevo-bi-140000345</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-announces-first-aprevo-bi-140000345</guid>
<pubDate>Tue, 10 Feb 2026 14:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company’s aprevo® Lumbar Bi-lateral Posterior System. The procedure was performed by Orthopedic Spine Surgeon CJ Kleck, M.D. at the University of Colorado Hospital in Denver, Colorado. “This clinical milestone strengthens our position as a leader in personalized, data-driven spine solutions</description>
</item>
<item>
<title>Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-announces-preliminary-revenue-fourth-130500575</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-announces-preliminary-revenue-fourth-130500575</guid>
<pubDate>Mon, 12 Jan 2026 13:05:00 GMT</pubDate>
<description>Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced preliminary and unaudited revenue for the fourth quarter and year ended December 31, 2025. Preliminary Q4 & FY 2025 Reven</description>
</item>
<item>
<title>Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-aprevo-lumbar-2-data-210500369</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-aprevo-lumbar-2-data-210500369</guid>
<pubDate>Tue, 06 Jan 2026 21:05:00 GMT</pubDate>
<description>CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically designed interbody implants significantly reduces mechanical complication–related reoperations in complex adult spinal deformity (ASD) surgery. The study compared 2-year revision rates among ASD patients re</description>
</item>
<item>
<title>Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-the-jp-morgan-2026-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-the-jp-morgan-2026-healthcare-conference</guid>
<pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier,</description>
</item>
<item>
<title>Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-announces-u-launch-aprevo-120000611</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-announces-u-launch-aprevo-120000611</guid>
<pubDate>Wed, 03 Dec 2025 12:00:00 GMT</pubDate>
<description>First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch WorkshopCARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Technology Platform for cervical fusion surgeries. Surgeons involved in the clinical evaluation will also present early clinical data at the Cervical Spine Research Society (CSRS)</description>
</item>
<item>
<title>Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference</guid>
<pubDate>Wed, 19 Nov 2025 05:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier,</description>
</item>
<item>
<title>Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-reports-third-quarter-2025-210100115</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-reports-third-quarter-2025-210100115</guid>
<pubDate>Thu, 06 Nov 2025 21:01:00 GMT</pubDate>
<description>Third quarter revenue of $13.1 million, representing 98% growth YoY Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the third quarter ended September 30, 2025. "We delivered another strong quarter with 98% revenue growth year-over-year, exp</description>
</item>
<item>
<title>Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-report-third-quarter-200100388</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-report-third-quarter-200100388</guid>
<pubDate>Thu, 23 Oct 2025 20:01:00 GMT</pubDate>
<description>CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial results after market close on Thursday, November 6, 2025. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. Conference Call Information To participate in this event, dial in approximately 5 to 10 minutes before th</description>
</item>
<item>
<title>Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-appoints-jennifer-kamocsay-130000375</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-appoints-jennifer-kamocsay-130000375</guid>
<pubDate>Mon, 29 Sep 2025 13:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, effective immediately. Ms. Kamocsay will serve as legal counsel for the Company and oversee compliance and corporate governance. Ms. Kamocsay brings more than two decades of corporate legal experience as in-</description>
</item>
<item>
<title>Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-selected-inclusion-russell-130000027</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-inc-selected-inclusion-russell-130000027</guid>
<pubDate>Mon, 22 Sep 2025 13:00:00 GMT</pubDate>
<description>CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that effective after market close on September 22, 2025, it has been added to the Russell 2000® Index. This was part of the planned additions of select companies to this Index that had their IPO in the third quarter of 2025. “Carlsmed’s inclusion in the Russell 2000 Index is furth</description>
</item>
<item>
<title>UPDATE - Carlsmed® Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-reports-second-quarter-2025-220900254</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-reports-second-quarter-2025-220900254</guid>
<pubDate>Thu, 28 Aug 2025 22:09:00 GMT</pubDate>
<description>Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo® technolo</description>
</item>
<item>
<title>Carlsmed® Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-reports-second-quarter-2025-200100106</link>
<guid isPermaLink="true">https://6ix.com/company/carlsmed-inc-common-stock/news/carlsmed-reports-second-quarter-2025-200100106</guid>
<pubDate>Thu, 28 Aug 2025 20:01:00 GMT</pubDate>
<description>Q2’25 revenue of $12.1 million, 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the second quarter ended June 30, 2025. “Our strong commercial performance was driven by the continued adoption of our highly differentiated AI-enabled aprevo® technolo</description>
</item>
</channel>
</rss>